Hahn Capital Management LLC Trims Position in Becton, Dickinson and Company (NYSE:BDX)

Hahn Capital Management LLC decreased its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 33.6% during the 3rd quarter, according to its most recent disclosure with the SEC. The firm owned 20,723 shares of the medical instruments supplier’s stock after selling 10,489 shares during the period. Becton, Dickinson and Company accounts for approximately 3.2% of Hahn Capital Management LLC’s portfolio, making the stock its 19th largest holding. Hahn Capital Management LLC’s holdings in Becton, Dickinson and Company were worth $4,996,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Jennison Associates LLC raised its stake in Becton, Dickinson and Company by 4.9% during the first quarter. Jennison Associates LLC now owns 402,350 shares of the medical instruments supplier’s stock worth $99,562,000 after purchasing an additional 18,786 shares during the period. Norden Group LLC raised its stake in Becton, Dickinson and Company by 2,086.7% during the first quarter. Norden Group LLC now owns 51,934 shares of the medical instruments supplier’s stock worth $12,853,000 after purchasing an additional 49,559 shares during the period. Avity Investment Management Inc. raised its stake in Becton, Dickinson and Company by 3.5% during the first quarter. Avity Investment Management Inc. now owns 162,687 shares of the medical instruments supplier’s stock worth $40,257,000 after purchasing an additional 5,527 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its stake in Becton, Dickinson and Company by 9.2% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 59,422 shares of the medical instruments supplier’s stock worth $14,481,000 after purchasing an additional 5,006 shares during the period. Finally, Axxcess Wealth Management LLC raised its stake in Becton, Dickinson and Company by 30.2% during the first quarter. Axxcess Wealth Management LLC now owns 11,051 shares of the medical instruments supplier’s stock worth $2,735,000 after purchasing an additional 2,565 shares during the period. Hedge funds and other institutional investors own 86.97% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on BDX. Evercore ISI increased their price target on shares of Becton, Dickinson and Company from $286.00 to $290.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. StockNews.com raised shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Thursday, August 8th. Stifel Nicolaus increased their price objective on shares of Becton, Dickinson and Company from $270.00 to $280.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. Citigroup raised shares of Becton, Dickinson and Company from a “neutral” rating to a “buy” rating and increased their price objective for the stock from $255.00 to $275.00 in a research report on Tuesday, October 1st. Finally, Raymond James dropped their price objective on shares of Becton, Dickinson and Company from $275.00 to $270.00 and set an “outperform” rating for the company in a research report on Friday, August 2nd. Nine research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus price target of $282.63.

Becton, Dickinson and Company Price Performance

BDX opened at $238.62 on Friday. The company has a fifty day simple moving average of $237.33 and a 200 day simple moving average of $235.16. The firm has a market cap of $68.96 billion, a price-to-earnings ratio of 52.56, a PEG ratio of 1.79 and a beta of 0.42. Becton, Dickinson and Company has a twelve month low of $218.75 and a twelve month high of $262.23. The company has a current ratio of 1.85, a quick ratio of 1.36 and a debt-to-equity ratio of 0.70.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, August 1st. The medical instruments supplier reported $3.50 earnings per share for the quarter, beating analysts’ consensus estimates of $3.31 by $0.19. The business had revenue of $4.99 billion during the quarter, compared to analyst estimates of $5.08 billion. Becton, Dickinson and Company had a net margin of 7.13% and a return on equity of 14.49%. The business’s revenue was up 2.3% on a year-over-year basis. During the same period last year, the business earned $2.96 EPS. Equities research analysts expect that Becton, Dickinson and Company will post 13.11 EPS for the current fiscal year.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.